SERPINS: METHODS OF THERAPEUTIC BETA-CELL REGENERATION AND FUNCTION
Compositions and methods of use are provided for improving β cell function and promoting pancreatic β cell proliferation in vitro, in vivo and ex vivo. The active agents of the pending invention comprise Serpin family peptides (e.g., SerpinB1), functional and structural analogs of Serpin family peptides and nucleic acids encoding Serpin family peptides, as well as active fragments thereof.
1 . Use of a Serpin peptide or active fragment, or an analog thereof as medicament.
2 . The use of claim 1 , wherein said Serpin peptide is SerpinB1.
3 . The use of claim 1 , wherein said Serpin analog is a known functional analog.
4 . The use of claim 1 , wherein said Serpin analog is a known structural analog.
5 . The use of claim 1 , wherein the subject has diabetes.
6 . The use of claim 1 , wherein the subject is at risk of developing diabetes.
7 . A Serpin peptide or active fragment, or an analog thereof for improving the β cell function in a subject.
8 . The peptide or active fragment, or analog of claim 7 , wherein said Serpin peptide is SerpinB1.
9 . The peptide or active fragment, or analog of claim 7 , wherein said Serpin analog is a known functional analog.
10 . The peptide or active fragment, or analog of claim 7 , wherein said Serpin analog is a known structural analog.
11 . The peptide or active fragment, or analog of claim 7 , wherein the subject has diabetes.
12 . The peptide or active fragment, or analog of claim 7 , wherein the subject is at risk of developing diabetes.
13 . A Serpin peptide or active fragment, or an analog thereof for promoting pancreatic β cell proliferation in a subject.
14 . The peptide or active fragment, or an analog of claim 13 , wherein said Serpin peptide is SerpinB1.
15 . The peptide or active fragment, or an analog of claim 13 , wherein said population of pancreatic β cells are in vivo.
16 . The peptide or active fragment, or an analog of claim 13 , wherein said population of pancreatic β cells are in vitro.
17 . The peptide or active fragment, or an analog of claim 13 , wherein said Serpin analog is a known functional analog.
18 . The peptide or active fragment, or an analog of claim 13 , wherein said Serpin analog is a known structural analog.
19 . The peptide or active fragment, or an analog of claim 13 , wherein increased pancreatic β cell proliferation in vivo is indicated by detecting increased glycemic control in the subject.
20 . An expression-construct encoding a Serpin peptide or active fragment, or analog thereof for improving the β cell function in a subject.
21 . The expression-construct encoding a Serpin peptide or active fragment, or analog thereof of claim 20 , wherein said encoded Serpin peptide is SerpinB1.
22 . The expression construct encoding a Serpin peptide or active fragment, or analog thereof of claim 20 , wherein said encoded Serpin peptide analog is a known functional analog.
23 . The expression construct encoding a Serpin peptide or active fragment, or analog thereof of claim 20 , wherein said encoded Serpin peptide analog is a known structural analog.
24 . The expression-construct encoding a Serpin peptide or active fragment, or analog thereof of claim 20 , wherein the subject has diabetes.
25 . The expression-construct encoding a Serpin peptide or active fragment, or analog thereof of claim 20 , wherein the subject is at risk of developing diabetes.
26 . The use of a Serpin peptide or active fragment, or an analog thereof for manufacturing of a medicament for improving the β cell function in a subject.
27 . The use of claim 26 , wherein said Serpin peptide is SerpinB1.
28 . The use of claim 26 , wherein said Serpin analog is a known functional analog.
29 . The use of claim 26 , wherein said Serpin analog is a known structural analog.
30 . The use of claim 26 , wherein the subject has diabetes.
31 . The use of claim 26 , wherein the subject is at risk of developing diabetes.
32 . The use of a Serpin peptide or active fragment, or an analog thereof for manufacturing of a medicament for promoting pancreatic β cell proliferation in a subject.
33 . The use of claim 32 , wherein said Serpin peptide is SerpinB1.
34 . The use of claim 32 , wherein said population of pancreatic β cells are in vivo.
35 . The use of claim 32 , wherein said population of pancreatic β cells are in vitro.
36 . The use of claim 32 , wherein said Serpin analog is a known functional analog.
37 . The use of claim 32 , wherein said Serpin analog is a known structural analog.
38 . The use of claim 32 , wherein increased pancreatic β cell proliferation in vivo is indicated by detecting increased glycemic control in the subject.
39 . The use of an expression construct encoding a Serpin peptide or active fragment, or analog thereof for manufacturing of a medicament for improving the β cell function in a subject.
40 . The use of claim 39 , wherein said encoded Serpin peptide is SerpinB1.
41 . The use of claim 39 , wherein said encoded Serpin peptide analog is a known functional analog.
42 . The use of claim 39 , wherein said encoded Serpin peptide analog is a known structural analog.
43 . The use of claim 39 , wherein the subject has diabetes.
44 . The use of claim 39 , wherein the subject is at risk of developing diabetes.